Charles Schneider

5.5k total citations
45 papers, 993 citations indexed

About

Charles Schneider is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Charles Schneider has authored 45 papers receiving a total of 993 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Charles Schneider's work include Pancreatic and Hepatic Oncology Research (10 papers), Cancer Genomics and Diagnostics (8 papers) and PARP inhibition in cancer therapy (8 papers). Charles Schneider is often cited by papers focused on Pancreatic and Hepatic Oncology Research (10 papers), Cancer Genomics and Diagnostics (8 papers) and PARP inhibition in cancer therapy (8 papers). Charles Schneider collaborates with scholars based in United States, Germany and United Kingdom. Charles Schneider's co-authors include Ursina Teitelbaum, Mark H. O’Hara, Kim A. Reiss, Susan M. Domchek, Thomas B. Karasic, Rosemarie Mick, Rashmi Tondon, Robert H. Vonderheide, Katherine L. Nathanson and Adam Raben and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Charles Schneider

42 papers receiving 977 citations

Peers

Countries citing papers authored by Charles Schneider

Since Specialization

Citations

This map shows the geographic impact of Charles Schneider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Schneider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Schneider more than expected).

Fields of papers citing papers by Charles Schneider

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Schneider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Schneider. The network helps show where Charles Schneider may publish in the future.

Co-authorship network of co-authors of Charles Schneider

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Schneider. A scholar is included among the top collaborators of Charles Schneider based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Schneider. Charles Schneider is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors 2025 ·Targeted Oncology ·Cathy Eng, Nehal J. Lakhani, Philip A. Philip, Charles Schneider, Benny Johnson, Adel Kardosh, Mark P. Chao, Amita Patnaik, (unknown), Yeon‐Ju Lee, Kai Song, (unknown), (unknown), Michael F. Howland, George A. Fisher, J. Randolph Hecht	3
2	A phase II study of maintenance rucaparib in patients with platinum sensitive, advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2 or PALB2: A four year survival update. 2024 ·Journal of Clinical Oncology ·(unknown), Mark H. O’Hara, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, (unknown), Katherine L. Nathanson, Robert H. Vonderheide, Susan M. Domchek	1
3	The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib 2023 ·Clinical Cancer Research ·Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, (unknown), Mark H. O’Hara, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, Erica L. Carpenter, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss	10
4	Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors 2023 ·British Journal of Cancer ·Jason J. Luke, Marwan Fakih, Charles Schneider, E. Gabriela Chiorean, Johanna C. Bendell, Rebecca Kristeleit, Razelle Kurzrock, Sarah P. Blagden, Irene Braña, Laura W. Goff, Kevin O’Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing	19
5	Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer 2022 ·The Oncologist ·Thomas B. Karasic, Timothy J. Brown, Charles Schneider, Ursina Teitelbaum, Kim A. Reiss, Tara C. Mitchell, Ryan Massa, Mark H. O’Hara, (unknown), (unknown), Ravi K. Amaravadi, Peter J. O’Dwyer	22
6	Predictive risk-score model for selection of patients with high-risk stage II colon cancer for adjuvant systemic therapy 2021 ·Surgery ·Richard J. Straker, (unknown), Adrienne B. Shannon, Douglas L. Fraker, Skandan Shanmugan, Charles Schneider, Najjia N. Mahmoud, John T. Miura, Giorgos C. Karakousis	7
7	Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer. 2021 ·Journal of Clinical Oncology ·Timothy J. Brown, Thomas B. Karasic, Charles Schneider, Ursina Teitelbaum, (unknown), Tara C. Mitchell, Ryan Massa, Mark H. O’Hara, (unknown), (unknown), Ravi K. Amaravadi, Peter J. O’Dwyer	3
8	Prognostic relevance of the posterior resection margin for predicting disease free survival in ampullary adenocarcinoma 2020 ·Surgical Oncology ·Charles Schneider, Mikael H. Sodergren, (unknown), Fiammetta Soggiu, Ricky H. Bhogal, A. Khan	0
9	Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer 2019 ·Journal of Clinical Oncology ·Athanassios Argiris, Shuli Li, P. Savvides, James Ohr, Jill Gilbert, Marshall Levine, Arnab Chakravarti, Missak Haigentz, Nabil F. Saba, Chukwuemeka Ikpeazu, Charles Schneider, Harlan A. Pinto, Arlene A. Forastiere, Barbara Burtness	74
10	Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation 2019 ·JCO Precision Oncology ·Shun Yu, Parul Agarwal, Ronac Mamtani, Heather Symecko, (unknown), Mark H. O’Hara, Peter J. O’Dwyer, Charles Schneider, Ursina Teitelbaum, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss	25
11	Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2 2019 ·Cancer Research ·(unknown), Rosemarie Mick, Mark H. O’Hara, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, Peter J. O’Dwyer, Erica L. Carpenter, (unknown), Mehran Makvandi, David A. Mankoff, Katherine L. Nathanson, Kara N. Maxwell, (unknown), (unknown), (unknown), Gregory L. Beatty, Susan M. Domchek	25
12	Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201 2019 ·Journal of Clinical Oncology ·Syma Iqbal, Shannon McDonough, Heinz‐Josef Lenz, David H. Ilson, Barbara Burtness, Chaitali Nangia, Afsaneh Barzi, Charles Schneider, Jane Jijun Liu, Efrat Dotan, Katherine A. Guthrie, Howard S. Höchster	9
13	Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis 2018 ·Oral Oncology ·Joshua D. Palmer, Charles Schneider, Neil Hockstein, Alexandra L. Hanlon, (unknown), Jon Strasser, (unknown), Michael Dzeda, Robert L. Witt, Adam Raben	18
14	Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: Updated results of an institutional clinical management approach 2015 ·Oral Oncology ·Tu Dan, David Raben, Charles Schneider, Neil Hockstein, Robert L. Witt, Michael Dzeda, (unknown), Adam Raben	25
15	The impact of balloon catheter dilation on frequency of sinus surgery in the United States 2014 ·Medical Devices Evidence and Research ·Chantal E. Holy, John M. Ellison, Charles Schneider, Howard L. Levine	14
16	A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen 2009 ·Investigational New Drugs ·Lida A. Mina, Ian E. Krop, Robin Zoň, Steven J. Isakoff, Charles Schneider, Menggang Yu, (unknown), (unknown), Yanping Wang, Maria K. Hristova‐Kazmierski, Oluwatoyin Shonukan, George W. Sledge, Kathy D. Miller	24
17	Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies 2009 ·The Oncologist ·Michael J. Guarino, Charles Schneider, (unknown), Julie R. Brahmer, Charles M. Rudin, Friedrich Graf Finckenstein, (unknown), Haolan Lu, Martin R. Weber, David S. Ettinger	18
18	Postoperative Management of Thyroid Carcinoma 2008 ·Surgical Oncology Clinics of North America ·(unknown), (unknown), Charles Intenzo, (unknown), Charles Schneider, Prakash Seshadri	0
19	Dual inhibition of the epidermal growth factor receptor (EGFR) pathway with the combination of cetuximab and erlotinib: A phase I study in patients with advanced solid malignancies 2007 ·Molecular Cancer Therapeutics ·Michael J. Guarino, Charles Schneider, (unknown), Julie R. Brahmer, Charles M. Rudin, Friedrich Graf Finckenstein, (unknown), Haolan Lu, Martin R. Weber, David S. Ettinger	2
20	A Dose-Escalation Study of Weekly Topotecan, Cisplatin, and Gemcitabine Front-Line Therapy in Patients with Inoperable Non-Small Cell Lung Cancer 2002 ·The Oncologist ·Michael J. Guarino, Charles Schneider, Stephen S. Grubbs, David D. Biggs, Andrew L. Himelstein, (unknown), (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact